Monoclonal antibodies in the treatment of dyslipidemia and cardiovascular risk lowering

Abstract

Review of the use of monoclonal antibodies in the measures of cardiovascular prevention focusing on the PCSK9 monoclonal antibodies.

Keywords

• PCSK9
• monoclonal antibodies
• LDL-cholesterol
• cardiovascular risk
• evolocumab